Results 131 to 140 of about 4,040 (201)

Effectiveness and safety of meropenem-vaborbactam versus ceftazidime-avibactam in multidrug-resistant Gram-negative infections: a systematic review and meta-analysis with trial sequential analysis. [PDF]

Antimicrob Agents Chemother
Mohammad S, Al Namer Y, Rahimeh W, Albalas M, Almangour TA.   +4 more
europepmc   +1 more source

Efficacy of ceftazidime-avibactam, meropenem-vaborbactam, and imipenem-relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland. [PDF]

Eur J Clin Microbiol Infect Dis, 2023
Nordmann P, Bouvier M, Poirel L.
europepmc   +1 more source

Meropenem–Vaborbactam Pharmacokinetics in Subjects with Chronic Renal Impairment, Including Hemodialysis [PDF]

Open Forum Infectious Diseases, 2017
Christopher M Rubino, David C Griffith, Sujata M Bhavnani, Jeffrey S Loutit, Brooke Lohse, Michael N Dudley, Paul G Ambrose   +6 more
openaire   +1 more source

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections [PDF]

Infectious Diseases and Therapy, 2021
openaire   +2 more sources

Genotypic Evolution of Klebsiella pneumoniae Sequence Type 512 during Ceftazidime/Avibactam, Meropenem/Vaborbactam, and Cefiderocol Treatment, Italy. [PDF]

Emerg Infect Dis, 2023
Arcari G, Cecilia F, Oliva A, Polani R, Raponi G, Sacco F, De Francesco A, Pugliese F, Carattoli A.   +8 more
europepmc   +1 more source

Characterisation of β-lactam/Vaborbactam activity in Klebsiella pneumoniae [PDF]

, 2019
Douglas, Ed J A
core  

Ceftazidime/Avibactam and Meropenem/Vaborbactam for the Management of Enterobacterales Infections: A Narrative Review, Clinical Considerations, and Expert Opinion. [PDF]

Antibiotics (Basel), 2023
Marino A, Campanella E, Stracquadanio S, Calvo M, Migliorisi G, Nicolosi A, Cosentino F, Marletta S, Spampinato S, Prestifilippo P, Stefani S, Cacopardo B, Nunnari G.   +12 more
europepmc   +1 more source

Meropenem/vaborbactam activity against carbapenem-resistant Klebsiella pneumoniae from catheter-related bloodstream infections. [PDF]

Front Cell Infect Microbiol
Sivori F, Francalancia M, Truglio M, Cavallo I, Pronesti C, Fabrizio G, Celesti I, Cazzani A, Furzi L, Pimpinelli F, Di Domenico EG.   +10 more
europepmc   +1 more source

Meropenem-Vaborbactam for Treatment of Carbapenem-Resistant Enterobacterales: A Narrative Review of Clinical Practice Evidence. [PDF]

Infect Dis Ther
Bassetti M, Giacobbe DR, Vena A, Poulakou G, Rossolini GM, Soriano A, Nicolau DP.   +6 more
europepmc   +1 more source

Continuous infusion of meropenem-vaborbactam for a KPC-3-producing Klebsiella pneumoniae bloodstream infection in a critically ill patient with augmented renal clearance. [PDF]

Infection, 2023
Larcher R, Laffont-Lozes P, Naciri T, Bourgeois PM, Gandon C, Magnan C, Pantel A, Sotto A.   +7 more
europepmc   +1 more source